Outcomes No. of studies No. of experiment No. of control MD 95% CI value (%)TC Total 13 1141 1097 -1.03 -1.46, -0.60 <0.001 95.2 Subgroup: follow-up 2 months 3 168 160 -1.41 -2.67, -0.15 <0.001 96.1 3 months 8 541 526 -1.02 -1.61,-0.42 <0.001 95.1 6 months 1 75 75 -0.83 -1.16, -0.49 4 years 1 285 306 -0.29 -0.45, -0.13 Subgroup: prescription Xuezhikang 2 373 352 -0.63 -1.34, 0.07 <0.001 92.1 TG Total 13 1141 1097 -0.93 -1.32, -0.53 <0.001 94.3 Subgroup: follow-up 2 months 3 168 160 -1.02 -2.06, -0.03 <0.001 94.8 3 months 8 541 526 -1.03 -1.54, -0.53 <0.001 93.3 6 months 1 75 75 -0.697 -1.026, -0.367 4 years 1 285 306 -0.062 -0.223, 0.099 Subgroup: prescription Xuezhikang 2 373 352 -0.46 -1.27,0.35 <0.001 94.2 HDL Total 11 1068 1024 0.72 0.41, 1.02 <0.001 90.7 Subgroup: follow-up 2 months 1 68 60 1.39 1.01, 1.78 3 months 8 619 604 0.8 0.54, 1.06 <0.001 79.5 6 months 1 75 75 0.096 -0.224, 0.417 4 years 1 306 285 0.141 -0.02,0.3 Subgroup:prescription Xuezhikang 2 373 352 0.29 -0.06, 0.63 0.066 70.5 LDL Total 14 1243 1199 -1.20 -1.61, -0.79 <0.001 95.2 Subgroup: follow-up 2 months 2 110 118 -0.88 -1.15, -0.6 0.711 0 3 months 10 744 729 -1.38 -1.95, -0.81 <0.001 95.8 6 months 1 75 75 -0.898 -1.23, -0.56 4 years 1 306 285 -0.459 -0.62, -0.3 Subgroup: prescription Xuezhikang 2 373 352 -0.49 -0.64, -0.34 0.337 0 FBG Total 13 1143 1045 -0.5 -0.67, -0.33 <0.001 72.4 Subgroup: follow-up 2 months 4 358 275 -0.44 -0.73, -0.15 0.04 64.9 3 months 8 725 710 -0.49 -0.7, -0.27 <0.001 76.5 6 months 1 60 60 -0.886 -1.26, -0.51 Subgroup: prescription Tongxinluo 2 303 303 -0.43 -0.86, -0.01 0.009 85.2 HbA1c Total 9 679 664 -1.159 -1.85, -0.47 <0.001 96.9 Subgroup: follow-up 3 months 8 619 604 -0.95 -1.63, -0.28 <0.001 96.6 6 months 1 60 60 -2.85 -3.36,-2,3 2hPG Total 10 948 850 -0.58 -1, -0.16 <0.001 94.5 Subgroup: follow-up 2 months 4 358 275 -0.42 -0.72, -0.11 0.02 68.4 3 months 6 575 590 -0.69 -1.37, -0.01 <0.001 96.6 Subgroup: prescription Tongxinluo 2 303 303 -1.42 -3.33, 0.49 <0.001 99